Bulging order book for bioconjugates lifts WuXi XDC profits
The provider of outsourced pharmaceutical services has delivered unexpectedly strong half-year earnings and has launched its first overseas production hub Key Takeaways: WuXi XDC began operations in August at a…
Recent Articles
RELATED ARTICLES
-
WuXi AppTec wages buyback campaign as U.S. pressure mounts
2359.HK603259.SHG - Mega licensing deal lifts 3SBio profits but core sales slip
- Rethinking bigger Is better: China’s long march toward higher-capacity energy storage cells
-
BRIEF: WuXi Biologics maintains full-year revenue guidance for up to 17% growth
2269.HK
- Insilico revenue soars above $100 million on AI drug partnerships
-
GDS lifts EBITDA outlook as AI-driven bookings hit record
GDS.US
- Jacobio Pharma poised to turn a profit from precision cancer drugs
